As breakthroughs in CAR-T cell therapies reshaped the autoimmune landscape, attention was shifting toward the enormous potential of T-cell engagers (TCEs) to deliver safer, more scalable, and physician-friendly treatments in 2025. With innovations in CD3 affinity tuning, selective B-cell depletion, CRS mitigation, and novel autoimmune target discovery, TCEs were perfectly positioned to revolutionize immunology beyond oncology.

The T-Cell Engager for Autoimmune Disease Summit was the first and only hyper-focused industry event dedicated exclusively to accelerating TCE development for autoimmune and inflammatory disorders. This three-day forum united leading immunology researchers, biotech pioneers, and pharma executives to tackle the most pressing challenges in engineering, safety, and clinical translation.